Trial Profile
Phase I/II BNC105P combination study, evaluating recommended dose of BNC105P and objective response rate, in partially platinum sensitive ovarian cancer patients in first or second relapse.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs BNC 105 (Primary) ; Carboplatin; Gemcitabine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bionomics
- 20 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 17 Apr 2015 According to a Bionomics media release, biomarker data from this trial will be presented as a part of a pooled analysis of this and two other trials at the American Association for Cancer Research (AACR) 106th Annual Meeting.
- 04 Feb 2014 Enrolment of the phase I part of this trial was completed in 2013, according to a Bionomics media release. In total, 15 patients were recruited and have received treatment.